Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... The North America Thermal Protective ... for detailed analysis of the growth trends and ... $616.3 million by 2018, growing at a CAGR ... through the TOC of the North America Thermal ... of the in-depth analysis and industry segmentation supported ...
    (Date:11/26/2014)... and PHILADELPHIA , Nov. 26, 2014 ... and unforgiving environments. Human exploration of space requires astronauts ... ensure mission safety and success, and prevent potential errors ... mission success, little is known about how cognition is ... are primarily affected. Now, Penn Medicine researchers ...
    (Date:11/26/2014)... The ETC (Emerging Technology Centers) ... announced today that applications for AccelerateBaltimore™ (AB) 2015 ... you have a big idea?,” asked ETC’s President ... about it. AccelerateBaltimore helps you and your big ... 13 weeks.” Interested game changers with “big ...
    (Date:11/26/2014)... 25, 2014 SonaCare Medical, a ... (HIFU) devices, recently participated in the American Urology ... 360° .” Key opinion leaders in urology presented ... to small renal masses while attendees had the ... technologies in hands-on labs. Attendees at the Los ...
    Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
    ... Nov. 3 Altogen Biosystems (http://www.altogen.com ),announced ... laboratories and research facilities for animal testing. Transfection ... introduce DNA and RNA molecules,into cells and tissues. ... barriers and deliver a gene or a small ...
    ... Nov. 3 Nile Therapeutics,Inc., (Nasdaq: NLTX ), ... at the following upcoming investor conferences:, -- Rodman ... ET,in the Kennedy II room on Monday, November 10, ... -- Lazard Capital Markets 5th Annual Healthcare Conference at ...
    ... Metabolex, Inc., a,biopharmaceutical company focused on the ... the treatment of metabolic diseases,announced that two ... been,recognized in Windhover,s "Top 10 most interesting ... MBX-2982, a potential,first-in-class treatment for type 2 ...
    Cached Biology Technology:Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent 2Nile Therapeutics to Present at Two Upcoming Investor Conferences 2Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 2Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities 3
    (Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
    (Date:11/5/2014)... -Individuals show great diversity in their ability to identify ... greatly differ in their perceptual evaluation of odors, with ... , Sex differences in olfactory detection may ... be connected to one,s perception of smell, which is ... olfactory superiority has been suggested to be cognitive or ...
    (Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
    Breaking Biology News(10 mins):Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
    ... 2010 There,s a war occurring each day in our ... by UC Irvine,s Kailen Mooney suggests the outcome of ... study published online Friday, March 26, in the journal ... a group of flowering plants found throughout the Western hemisphere. ...
    ... A new test developed by Japanese scientists may revolutionize ... a research report published online in The FASEB ... proteins in the spinal fluid known to be one ... impairment in Alzheimer,s patients: high molecular weight A-Beta oligomers. ...
    ... novel research project spearheaded by the University of Leicester and ... on the way people perceive art. By bringing together ... from each other principles of visual perception. In the process ... insights into what truly lies in the eye of the ...
    Cached Biology News:New research indicates plants can grow quickly or ward off hungry insects, but not both 2New test takes guesswork out of diagnosing early-stage Alzheimer's disease 2Beauty is in the eye of the beholder? 2
    Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
    LAB/Probe Mouse-Rabbit DAB Kit...
    Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
    G-protein coupled purinergic receptor P2Y8...
    Biology Products: